Aliyu SamailaUsmanu Danfodiyo University Sokoto, Nigeria
Title: Health outcomes of different cervical cancer therapies among patients in two tertiary hospitals in Nigeria
Objectives: To evaluate the health outcomes (including symptoms’ resolution, adverse events (AEs) profile, and 1-year survival rate) of different cervical cancer (CC) therapies among patients in two tertiary hospitals in Nigeria.
Methods: This study employed a prospective longitudinal design with a 12-month patient follow-up. It was conducted at Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto, and Ahmadu Bello University Teaching Hospital (ABUTH), Zaria, Kaduna state, North-Western Nigeria. Data of 157 eligible CC patients was collected at baseline and after treatment courses/radiation fractions. Data analysis was done with appropriate descriptive and inferential statistics using SPSS V. 20 for windows. P < 0.05 was considered statistically significant.
Results: Patients who received chemoradiation therapy (CRT), 29 (100.0%), adjuvant chemoradiation therapy (CRTS), 9 (100.0%), adjuvant chemotherapy (CTS), 6 (100.0%) and chemotherapy (CT), 27 (28.1%) (P < 0.001) reported per vaginal bleeding (PVB) to have been completely stopped after therapy. Patients who received CT 4 (9.8%) experienced grade 3 anaemia; leucopaenia was experienced by patients who received CT 27 (54.0%) and CRT 20 (52.6%), P = 0.004. Grade 2 creatinine increase was observed in patients who received CRT 3 (8.1%) and CT 2 (3.1%), P = 0.013. There was no significant association between the therapy option received and 1-year survival rate of the patients within the clinical stage. However, age (OR = 0.257, P = 0.042), number of comorbidities (OR = 0.123, P = 0.039) and number of complications (OR = 0.013, P < 0.001) were found to be the independent predictors of survival.
Conclusion: Chemoradiation and adjuvant therapies were associated with the best resolution of symptoms, while CT and CRT had high frequencies and severity of AEs. Therapy options were not associated with 1-year survival rates.
Aliyu Samaila has completed his PHD at the age of 38 years from University of Nigeria Nsukka, Enugu State. He is the head of clinical pharmacy and pharmacy practice department of Usmanu Danfodiyo University Sokoto, Nigeria. He has over 20 publications. He has been serving as a reviewer of several reputed journals.